Table 2 The genotype frequencies of MMP polymorphisms between the control group and patients with moyamoya disease
Characteristic | Control (n = 243) | Moyamoya (n = 107) | AOR (95% CI) | P a | P b |
|---|---|---|---|---|---|
MMP2 -1575G > A (rs243866) | |||||
GG | 210 (86.4) | 92 (86.0) | 1.00 (reference) | ||
GA | 33 (13.6) | 15 (14.0) | 1.03 (0.53-2.00) | 0.94 | 0.94 |
AA | 0 (0.0) | 0 (0.0) | NA | NA | |
Dominant (GG vs. GA + AA) | 1.03 (0.53-2.00) | 0.94 | 0.94 | ||
Recessive (GG + GA vs. AA) | NA | NA | |||
HWE P | 0.256 | 0.436 | |||
MMP2 -1306C > T (rs243865) | |||||
CC | 222 (91.4) | 99 (92.5) | 1.00 (reference) | ||
CT | 21 (8.6) | 8 (7.5) | 0.87 (0.37-2.05) | 0.75 | 0.75 |
TT | 0 (0.0) | 0 (0.0) | NA | NA | |
Dominant (CC vs. CT + TT) | 0.87 (0.37-2.05) | 0.75 | 0.75 | ||
Recessive (CC + CT vs. TT) | NA | NA | |||
HWE P | 0.481 | 0.688 | |||
MMP3 -1171 5a/6a (rs3025058) | |||||
6a6a | 187 (77.0) | 78 (72.9) | 1.00 (reference) | ||
6a5a | 51 (21.0) | 23 (21.5) | 1.07 (0.61-1.89) | 0.81 | 0.81 |
5a5a | 5 (2.1) | 6 (5.6) | 2.92 (0.85-10.00) | 0.09 | 0.18 |
Dominant (6a6a vs. 6a5a + 5a5a) | 1.24 (0.74-2.10) | 0.42 | 0.56 | ||
Recessive (6a6a + 6a5a vs. 5a5a) | 3.00 (0.88-10.20) | 0.08 | 0.18 | ||
HWE P | 0.493 | 0.027 | |||
MMP9 -1562C > T (rs3918242) | |||||
CC | 195 (80.2) | 85 (79.4) | 1.000 (reference) | ||
CT | 47 (19.3) | 19 (17.8) | 0.91 (0.50-1.66) | 0.76 | 0.92 |
TT | 1 (0.4) | 3 (2.8) | 6.12 (0.62-60.42) | 0.12 | 0.24 |
Dominant (CC vs. CT + TT) | 1.03 (0.58-1.83) | 0.92 | 0.92 | ||
Recessive (CC + CT vs. TT) | 6.45 (0.65-63.68) | 0.11 | 0.24 | ||
HWE P | 0.298 | 0.149 | |||
MMP9 Q279R (rs17576) | |||||
GG | 100 (41.2) | 56 (52.3) | 1.000 (reference) | ||
GA | 120 (49.4) | 46 (43.0) | 0.66 (0.41-1.07) | 0.09 | 0.11 |
AA | 23 (9.5) | 5 (4.7) | 0.36 (0.13-1.00) | 0.05 | 0.10 |
Dominant (GG vs. GA + AA) | 0.61 (0.39-0.98) | 0.04 | 0.10 | ||
Recessive (GG + GA vs. AA) | 0.45 (0.16-1.22) | 0.11 | 0.11 | ||
HWE P | 0.127 | 0.244 | |||